Hotsia.Com : เที่ยวสะใจ

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

---

CKD and metabolic acidosis

Metabolic acidosis is a common and significant complication in patients with Chronic Kidney Disease (CKD), particularly in the later stages. It occurs when the kidneys lose their ability to maintain acid-base balance, leading to the accumulation of acid in the body. This condition contributes to various adverse outcomes, including bone disease, muscle wasting, cardiovascular complications, and faster progression of CKD itself. Managing metabolic acidosis is a critical aspect of CKD care, as it can help mitigate its harmful effects and improve the patient’s quality of life.

Overview of Acid-Base Balance and the Role of the Kidneys

The body maintains a delicate balance between acids and bases to keep the blood pH within a narrow range (7.35-7.45). This balance is essential for proper cellular function. Acid is generated from normal metabolic processes, such as the breakdown of proteins and fats, and the body must continuously buffer and excrete this acid load to prevent acidosis.

• The kidneys play a crucial role in maintaining acid-base homeostasis by:
  1. Excreting hydrogen ions (H⁺): The kidneys remove excess hydrogen ions generated from metabolism.
  2. Reabsorbing bicarbonate (HCO₃⁻): Bicarbonate acts as a buffer to neutralize acids, and the kidneys reabsorb filtered bicarbonate to maintain an adequate buffer system.
  3. Generating new bicarbonate: The kidneys can produce new bicarbonate in response to increased acid load to restore acid-base balance.

In CKD, the kidneys’ ability to excrete hydrogen ions and regenerate bicarbonate is impaired, leading to the accumulation of acid and the development of metabolic acidosis.

Pathophysiology of Metabolic Acidosis in CKD

Metabolic acidosis in CKD results from the progressive decline in kidney function, particularly when the glomerular filtration rate (GFR) falls below 40–50 mL/min/1.73 m² (usually in CKD stages 3 to 5). Several mechanisms contribute to the development of metabolic acidosis in CKD:

1. Impaired Hydrogen Ion Excretion:

• The kidneys are responsible for excreting excess hydrogen ions (H⁺) generated from normal metabolic processes, such as the breakdown of proteins and the production of organic acids. In CKD, as nephron function declines, the kidneys lose their capacity to secrete hydrogen ions, leading to retention of acid in the body.
• Normally, the kidneys excrete acid in the form of ammonium (NH₄⁺) and titratable acids (such as phosphate). However, in CKD, the ability to produce and excrete ammonium is reduced, further limiting acid excretion.

2. Decreased Bicarbonate Reabsorption and Generation:

• Bicarbonate (HCO₃⁻) is a critical buffer that neutralizes excess acid in the blood. In CKD, the kidneys’ ability to reabsorb bicarbonate from the filtrate is impaired, resulting in bicarbonate wasting.
• Additionally, the kidneys are less able to generate new bicarbonate to compensate for acid accumulation. This combination of reduced bicarbonate reabsorption and generation leads to a decline in serum bicarbonate levels, a hallmark of metabolic acidosis.

3. Increased Acid Production:

• CKD patients often have increased endogenous acid production due to dietary factors (such as high intake of animal proteins) and metabolic changes associated with CKD. The kidneys are unable to match this increased acid load with adequate excretion, leading to acidosis.

4. Hyperkalemia and Acidosis:

• Hyperkalemia, which is common in CKD, can further exacerbate metabolic acidosis. High levels of potassium (K⁺) in the blood interfere with hydrogen ion secretion in the kidneys, as both potassium and hydrogen compete for excretion in the distal tubules. This contributes to the acid retention seen in CKD.

Types of Metabolic Acidosis in CKD

There are two primary types of metabolic acidosis that can occur in CKD:

1. High-Anion Gap Metabolic Acidosis:
   • This form of metabolic acidosis occurs due to the accumulation of unmeasured anions, such as sulfates, phosphates, and organic acids, that are typically excreted by the kidneys. The anion gap is calculated as the difference between the concentrations of sodium and the sum of chloride and bicarbonate. In CKD, the anion gap increases due to the retention of acids like sulfates and phosphates.
   • High-anion gap metabolic acidosis is common in advanced CKD (stages 4 and 5) and end-stage renal disease (ESRD), when the kidneys’ ability to excrete these acids is severely impaired.
2. Normal-Anion Gap (Hyperchloremic) Metabolic Acidosis:
   • In early-stage CKD, patients may develop normal-anion gap (or hyperchloremic) metabolic acidosis due to a loss of bicarbonate in the urine without a significant accumulation of unmeasured anions. This form of acidosis results from a defect in bicarbonate reabsorption in the proximal tubules, leading to bicarbonate loss and chloride retention.
   • This type of acidosis can occur in mild to moderate CKD (stages 1 to 3).

Clinical Consequences of Metabolic Acidosis in CKD

Metabolic acidosis has a wide range of harmful effects on various organ systems, contributing to the progression of CKD and increasing the risk of morbidity and mortality.

1. Bone Disease (Renal Osteodystrophy):

• Chronic metabolic acidosis leads to bone demineralization as the body attempts to buffer excess acid. To neutralize the acid, calcium and phosphate are released from bones, resulting in bone resorption and weakening.
• Over time, this can contribute to the development of renal osteodystrophy, a form of metabolic bone disease that leads to bone pain, fractures, and skeletal deformities in CKD patients.

2. Muscle Wasting:

• Metabolic acidosis is a significant cause of muscle wasting (cachexia) in CKD. Acid accumulation stimulates protein catabolism in muscle tissue, leading to the breakdown of muscle proteins and loss of muscle mass. This process is mediated by increased activity of proteolytic enzymes (such as ubiquitin-proteasome pathway enzymes) in response to acidosis.
• Muscle wasting contributes to weakness, reduced physical function, and poor quality of life in CKD patients.

3. Progression of CKD:

• Metabolic acidosis accelerates the progression of CKD through various mechanisms, including:
  • Tubular cell injury: Acid retention damages renal tubular cells and promotes interstitial fibrosis, leading to further kidney injury.
  • Increased endothelin production: Acidosis stimulates the production of endothelin, a potent vasoconstrictor, which reduces blood flow to the kidneys and contributes to ischemic injury.
• Studies have shown that metabolic acidosis is associated with faster decline in kidney function and higher rates of progression to end-stage renal disease (ESRD).

4. Cardiovascular Disease:

• Metabolic acidosis is linked to an increased risk of cardiovascular complications in CKD patients. Acidosis promotes systemic inflammation, endothelial dysfunction, and vascular calcification, all of which contribute to the development of cardiovascular disease.
• Additionally, metabolic acidosis can worsen heart function by impairing myocardial contractility and increasing the risk of arrhythmias.

5. Hyperkalemia:

• Metabolic acidosis exacerbates hyperkalemia, a condition in which elevated potassium levels can lead to dangerous cardiac arrhythmias and sudden death. Acidosis promotes the movement of potassium from cells into the bloodstream, raising serum potassium levels.

6. Insulin Resistance:

• Metabolic acidosis impairs glucose metabolism and contributes to insulin resistance, which is particularly problematic in CKD patients with diabetes. Acidosis interferes with insulin signaling pathways, making it harder for the body to regulate blood sugar levels.

Diagnosis of Metabolic Acidosis in CKD

Diagnosis of metabolic acidosis in CKD involves evaluating acid-base balance through blood tests and monitoring for associated complications.

1. Serum Bicarbonate Levels:
   • The primary diagnostic test for metabolic acidosis is measuring serum bicarbonate (HCO₃⁻) levels. In metabolic acidosis, serum bicarbonate levels are typically low (<22 mEq/L). Bicarbonate levels should be monitored regularly in CKD patients, especially in those with stages 3-5 CKD.
2. Arterial Blood Gas (ABG) Analysis:
   • In more severe cases of metabolic acidosis, arterial blood gas (ABG) analysis is used to assess blood pH, partial pressure of carbon dioxide (PaCO₂), and bicarbonate levels. A low pH (<7.35) indicates acidosis, and low bicarbonate confirms the metabolic component of the acidosis.
3. Anion Gap:
   • Calculating the anion gap helps determine the type of metabolic acidosis (high or normal anion gap). The anion gap is calculated using the formula:
     • Anion gap = [Na⁺] – ([Cl⁻] + [HCO₃⁻])
   • A high anion gap suggests the accumulation of unmeasured anions, while a normal anion gap points to bicarbonate loss.
4. Electrolyte Panel:
   • Monitoring serum electrolytes, including potassium, sodium, and chloride, is essential in managing metabolic acidosis in CKD. Hyperkalemia is often seen in conjunction with acidosis and must be addressed.

Management of Metabolic Acidosis in CKD

The management of metabolic acidosis in CKD focuses on correcting acid-base imbalances, preventing complications, and slowing the progression of kidney disease. The mainstay of treatment is the use of alkali therapy (oral bicarbonate supplementation), along with lifestyle modifications and dietary interventions.

1. Oral Bicarbonate Therapy:

• Sodium bicarbonate is the most commonly used alkali agent for correcting metabolic acidosis in CKD. It neutralizes excess acid and helps raise serum bicarbonate levels, improving acid-base balance.
• The goal of bicarbonate therapy is to maintain serum bicarbonate levels in the range of 22-26 mEq/L, which is considered normal.
• Typical dosing starts at 650 mg to 1,300 mg of sodium bicarbonate orally, taken two or three times daily, with adjustments based on the patient’s serum bicarbonate levels.

2. Alternative Alkali Therapies:

• For patients who cannot tolerate sodium bicarbonate due to fluid overload or hypertension, other alkali agents such as sodium citrate (Shohl’s solution or Bicitra) may be used. Sodium citrate is metabolized to bicarbonate in the liver and has similar effects to sodium bicarbonate.

3. Dietary Management:

• Reducing the intake of acidic foods, particularly those high in protein (such as meat and dairy products), can help reduce acid load and slow the progression of metabolic acidosis. A diet lower in animal protein and higher in fruits and vegetables can help alkalinize the body.
• Plant-based diets are often recommended in CKD patients with metabolic acidosis, as they produce less acid during metabolism and provide a source of bicarbonate precursors.

4. Managing Hyperkalemia:

• Treating hyperkalemia is essential in CKD patients with metabolic acidosis. This may involve reducing potassium intake, adjusting medications (e.g., potassium-sparing diuretics), and using potassium binders to lower serum potassium levels.

5. Treatment of Underlying CKD:

• Slowing the progression of CKD through optimal management of blood pressure, blood sugar levels (in diabetic patients), and avoiding nephrotoxic medications can help reduce the risk of metabolic acidosis.

Long-Term Outcomes and Prognosis

Metabolic acidosis is associated with worse outcomes in CKD patients, including faster disease progression, increased morbidity, and higher mortality rates. However, studies have shown that correcting metabolic acidosis with bicarbonate therapy can slow the decline in kidney function, reduce the risk of complications, and improve overall survival. Early identification and treatment of metabolic acidosis are crucial for improving the long-term prognosis of CKD patients.

Conclusion

Metabolic acidosis is a common complication of CKD that contributes to a range of harmful effects, including bone disease, muscle wasting, cardiovascular complications, and faster progression of kidney dysfunction. It arises from the kidneys’ inability to excrete hydrogen ions and reabsorb bicarbonate, leading to acid retention and a decline in serum bicarbonate levels. Early recognition and treatment with alkali therapy (typically sodium bicarbonate) can help prevent complications and improve outcomes in CKD patients. Along with dietary modifications and management of hyperkalemia, correcting metabolic acidosis is an essential component of comprehensive CKD care.

The Chronic Kidney Disease Solution™ By Shelly Manning It is an eBook that includes the most popular methods to care and manage kidney diseases by following the information provided in it. This easily readable eBook covers up various important topics like what is chronic kidney disease, how it is caused, how it can be diagnosed, tissue damages caused by chronic inflammation, how your condition is affected by gut biome, choices for powerful lifestyle and chronic kidney disease with natural tools etc.

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. I share my experiences on www.hotsia.com